[November 13, 2012]

US Environmental Protection Agency Issues Featured News Article Covering Cooperation With NanoLogix

NanoLogix (OTC Markets: NNLX) is the subject of a featured news article released last week by the US Environmental Protection Agency. The article covers the progress of an ongoing Cooperative Research and Development Agreement (CRADA) in place between the EPA and NanoLogix. The objective of the CRADA is to develop a comprehensive water quality test kit for use in testing drinking and source waters in the EPA's ten regions.

The article can be accessed on the EPA's site at the following link: http://www.epa.gov/nerl/features/nanologix.html

NanoLogix is pleased to announce sales experienced a significant increase in Q3. Essentially all of Q3 and current sales have been, and are, directly to the US Federal government or to Corporations for use on classified US Government projects. These sales are comprised of BNP kits and filled Petri plates. Major marketing for BNP and BioNanoFilter (BNF) bacteria detection kits is pending publication of two recently completed third-party studies in peer-reviewed science journals.

The company has had increasing interest in both its BioNanoPore (BNP) Petri-based sandwiched-membrane bacteria detection kits and also in standard filled Petri pates, both packed in NanoLogix's proprietary extended-life packaging. The internally developed patent pending packaging enables storage of both BNP and Petri for over one year in cold storage, and for at least three months at room temperature.

NanoLogix is honored to welcome Giles Manley, MD to the NanoLogix Science Advisory Board (SAB). Dr. Manley brings a wealth of medical, legal and business knowledge to the SAB.

Dr. Manley's acceptance statement: "I am grateful for the invitation, and very excited about being part of NanoLogix by serving on their Science Advisory Board. What NanoLogix has accomplished over the last several years is truly amazing. There is no comparable system in the world that can deliver bacterial identification as cost effectively, quickly and accurately as their BNF and BNP product line… Through my career I have formed acquaintances with the Chiefs of Obstetrics at some of the top medical institutions in our country. I will make a concerted effort to get the necessary trials started and finished at places such as Harvard, Johns Hopkins and other institutions. I am hopeful that by the end of 2013 the standard for GBS screening will include our near-15 minute test at time of labor."

More information on Dr. Manley and the SAB can be found at: http://nanologix.com/about/team.html

About NanoLogix, Inc.

NanoLogix is a biotechnology company focused primarily on rapid diagnostics. Its products offer accelerated detection and identification of microorganisms. In addition to medical and homeland security applications, NanoLogix technology is applicable in pharmaceutical, industrial, veterinary and environmental testing. Patents granted to NanoLogix can be used in the areas of applied microbiology, soil microbiology, microbial physiology, molecular biology, pharmacology, pharmaco-kinetics, and antibiotic sensitivity. For more information visit: www.nanologix.com.

This press release contains statements, which may constitute "forward- looking statements" within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Those statements include statements regarding the intent, belief or current expectations of NanoLogix, Inc., and members of its management as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. The Company undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results.

[ Back To HTML5's Homepage ]